Pyrroles
Research News and Information

Monday, November 23, 2009

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

18 Oct 2009 OBJECTIVES: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. BACKGROUND: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair ... Read more...

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

12 Oct 2009 The radical species produced following one-electron reduction of tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide, TPZ) by cytochrome P(450) reductase-enriched microsomes have been investigated using electron paramagnetic resonance (EPR) ... Read more...

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.

11 Oct 2009 BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC). METHODS: We examined the activity of sunitinib ... Read more...

Latest indexed articles for 'Pyrroles'

These are the very latest articles for this heading:

• Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. 30 Oct 2009
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects. 18 Oct 2009
• Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. 12 Oct 2009
• Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. 11 Oct 2009
• Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. 11 Oct 2009
• Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica. 6 Oct 2009
• Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065. 6 Oct 2009
• Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. 29 Sep 2009
• Development and maturation of invariant NKT cells in the presence of lysosomal engulfment. 29 Sep 2009
• Promoting neurite outgrowth from spiral ganglion neuron explants using polypyrrole/BDNF-coated electrodes. 29 Sep 2009
• Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. 29 Sep 2009
• Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study. 29 Sep 2009
• Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. 27 Sep 2009
• Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways. 26 Sep 2009
• Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. 23 Sep 2009
• [The ram and the oat bag] 22 Sep 2009
• Thymic stromal lymphopoietin induction by polyinosinic:polycytidylic acid in human keratinocytes is preferentially mediated through protein kinase R and retinoid-inducible gene I and not Toll-like receptor 3. 17 Sep 2009
• Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. 16 Sep 2009
• Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. 13 Sep 2009
• Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. 13 Sep 2009

See a longer list of these articles.

Technical information about 'Pyrroles'

Definition: Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.

Chemical name: 1-aza-2,4-cyclopentadiene

Registry Number: 0

Descriptor UI: D011758

Alternative terms: Pyrroles;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D03.383.129.578;